{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:12Z","timestamp":1790888352122,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.cct.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T13:16:03Z","timestamp":1460380563000},"page":"119-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial"],"prefix":"10.1016","volume":"48","clinical-trial-number":[{"clinical-trial-number":"nct00345839","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Safa","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Montez-Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cct.2016.04.001_bb0005","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov","volume":"63","author":"Inrig","year":"2014","journal-title":"Am. J. Kidney Dis.: Off. J. Natl. Kidney Found."},{"issue":"7491","key":"10.1016\/j.cct.2016.04.001_bb0010","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","article-title":"Validity of composite end points in clinical trials","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.cct.2016.04.001_bb0015","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"J. Am. Med. Assoc."},{"issue":"7597","key":"10.1016\/j.cct.2016.04.001_bb0020","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.cct.2016.04.001_bb0025","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ahj.2010.12.026","article-title":"Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial","volume":"161","author":"Armstrong","year":"2011","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.cct.2016.04.001_bb0030","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2307\/2531158","article-title":"Procedures for comparing samples with multiple endpoints","volume":"40","author":"O'Brien","year":"1984","journal-title":"Biometrics"},{"issue":"30","key":"10.1016\/j.cct.2016.04.001_bb0035","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/sim.3923","article-title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","volume":"29","author":"Buyse","year":"2010","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.cct.2016.04.001_bb0040","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4330\/wjc.v7.i1.1","article-title":"Opportunities and challenges of clinical trials in cardiology using composite primary endpoints","volume":"7","author":"Rauch","year":"2015","journal-title":"World J. Cardiol."},{"issue":"2","key":"10.1016\/j.cct.2016.04.001_bb0045","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.cct.2016.04.001_bb0050","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ahj.2012.07.002","article-title":"Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia","volume":"164","author":"Subherwal","year":"2012","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.cct.2016.04.001_bb0055","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview","volume":"2","author":"Chertow","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"issue":"7","key":"10.1016\/j.cct.2016.04.001_bb0060","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1093\/ndt\/gfr777","article-title":"Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"27","author":"Chertow","year":"2012","journal-title":"Nephrol. Dial. Transplant.: Off. Publ. Eur. Dial. Transplant Assoc.- Eur. Ren. Assoc."},{"issue":"26","key":"10.1016\/j.cct.2016.04.001_bb0065","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.04.001_bb9000","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16638312","article-title":"Analyzing Health-Related Quality of Life in the EVOLVE trial: the joint impact of treatment and clinical events","author":"Briggs","year":"2016","journal-title":"Med. Decis. Making"},{"issue":"408","key":"10.1016\/j.cct.2016.04.001_bb0070","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J. Am. Stat. Assoc."},{"issue":"11","key":"10.1016\/j.cct.2016.04.001_bb0075","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.cct.2016.04.001_bb0085","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"key":"10.1016\/j.cct.2016.04.001_bb0090","series-title":"Macro for greedy Matching Algorithm","author":"Kosanske","year":"2004"},{"issue":"5","key":"10.1016\/j.cct.2016.04.001_bb0095","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ahj.2011.01.023","article-title":"From batting average to wins above replacement to composite end points\u2014refining clinical research using baseball statistical methods","volume":"161","author":"Anstrom","year":"2011","journal-title":"Am. Heart J."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416300489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416300489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:52:22Z","timestamp":1536828742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416300489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":19,"alternative-id":["S1551714416300489"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.04.001","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}